Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Zacks News
5 Stocks with Spectacular Earnings Charts
by Tracey Ryniec
These companies aren't just beating on earnings, their stocks are also on fire, hitting new 5-year highs.
Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
by Zacks Equity Research
The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.
ABT or BIO: Which Stock Has Better Potential Right Now?
by Zacks Equity Research
Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $83.69, moving +0.88% from the previous trading session.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $83.42 in the latest trading session, marking a +1.67% move from the prior day.
Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.
Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $81.24, marking a +0.62% move from the previous day.
The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
Top Research Reports for Mastercard, Disney & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Disney (DIS) and Abbott (ABT).
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $77.54 in the latest trading session, marking a +1.85% move from the prior day.
Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges
by Zacks Equity Research
We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.
Abbott (ABT) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $75.67, marking a -0.05% move from the previous day.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $75.64, marking a -0.81% move from the previous day.
Why Is Abbott (ABT) Up 3.6% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
by Zacks Equity Research
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes